{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:39Z","timestamp":1780549539128,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) often coexist and exacerbate cardiac dysfunction. This study aimed to evaluate the effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with T2DM and CHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 262 patients with T2DM and CHD admitted between January 2021 and January 2025. Patients were assigned to either a conventional treatment group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009137; standard CHD therapy plus metformin) or a dapagliflozin group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009125; standard CHD therapy, metformin, and dapagliflozin 10\u2005mg daily), with both groups treated for 4 weeks. Assessments included echocardiographic cardiac function, myocardial motion parameters, left ventricular pressure-strain loop (LV-PSL) indices, electrophysiological activity, exercise tolerance, and adverse cardiovascular events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were comparable between groups. The dapagliflozin group demonstrated superior clinical efficacy (93.60% vs. 76.64%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) and greater improvements in left ventricular ejection fraction, myocardial strain and work indices, and exercise tolerance (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.01). Dapagliflozin was also associated with enhanced cardiac electrophysiological activity, including longer QT and Tp-Te intervals and reduced ST depression (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.01). Adverse event rates did not differ significantly between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with T2DM and CHD, adding dapagliflozin to conventional therapy improved cardiac function, myocardial performance, electrophysiological parameters, and exercise tolerance without increasing adverse cardiovascular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1745362","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:35:14Z","timestamp":1780547714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Fang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Dalian University Affiliated Xinhua Hospital","place":["Dalian, Liaoning Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Dalian University Affiliated Xinhua Hospital","place":["Dalian, Liaoning Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e002867","DOI":"10.1136\/bmjdrc-2022-002867","article-title":"Level of education is associated with coronary heart disease and chronic kidney disease in individuals with type 2 diabetes: a population-based study","volume":"10","author":"Sl\u00e5tsve","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e073763","DOI":"10.1136\/bmjopen-2023-073763","article-title":"Mediterranean Diet and time-restricted eating as a cardiac rehabilitation approach for patients with coronary heart disease and pre-diabetes: the DIABEPIC-1 protocol of a feasibility trial","volume":"13","author":"Iglesies-Grau","year":"2023","journal-title":"BMJ Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41387-024-00285-3","article-title":"Mediterranean Diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial","volume":"14","author":"Podadera-Herreros","year":"2024","journal-title":"Nutr Diabetes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1359345","DOI":"10.3389\/fendo.2024.1359345","article-title":"Prognostic value of red blood cell distribution width-to-albumin ratio in ICU patients with coronary heart disease and diabetes mellitus","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12933-022-01715-1","article-title":"Disease patterns of coronary heart disease and type 2 diabetes harbored distinct and shared genetic architecture","volume":"21","author":"Xiao","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e38275","DOI":"10.2196\/38275","article-title":"Effect of Mobile phone text messaging self-management support for patients with diabetes or coronary heart disease in a chronic disease management program (SupportMe) on blood pressure: pragmatic randomized controlled trial","volume":"25","author":"Cheung","year":"2023","journal-title":"J Med Internet Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-023-01875-8","article-title":"Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions","volume":"22","author":"Chen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"111574","DOI":"10.1016\/j.diabres.2024.111574","article-title":"A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes","volume":"209","author":"Jiu","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12933-024-02344-6","article-title":"Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"23","author":"Pourafkari","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.pcd.2024.07.003","article-title":"Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005\u20132019","volume":"18","author":"Alshehri","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1243834","DOI":"10.3389\/fimmu.2023.1243834","article-title":"Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12933-024-02446-1","article-title":"Multiple triglyceride-derived metabolic indices and incident cardiovascular outcomes in patients with type 2 diabetes and coronary heart disease","volume":"23","author":"Tao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12933-023-01919-z","article-title":"The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia","volume":"22","author":"Li","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-025-02670-3","article-title":"Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease","volume":"24","author":"Li","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 diabetes mellitus and cardiovascular disease","volume":"14","author":"Henning","year":"2018","journal-title":"Future Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-981-15-2517-9_2","article-title":"Evidence in guidelines for treatment of coronary artery disease","volume":"1177","author":"Jia","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12872-022-02956-4","article-title":"Coronary calcium density in relation to coronary heart disease and cardiovascular disease in adults with diabetes or metabolic syndrome: the multi-ethnic study of atherosclerosis (MESA)","volume":"22","author":"Zhao","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-024-02175-5","article-title":"Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: cORDIOPREV randomised controlled trial","volume":"23","author":"Ojeda-Rodriguez","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","volume":"20","author":"Wong","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/nu16081249","article-title":"Association between diet quality and risk of type 2 diabetes Mellitus in patients with coronary heart disease: findings from the CORDIOPREV study","volume":"16","author":"Rivas-Garcia","year":"2024","journal-title":"Nutrients"},{"key":"B21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/ijerph19020647","article-title":"Coronary heart disease in type 2 diabetes Mellitus: genetic factors and their mechanisms, gene-gene, and gene-environment interactions in the Asian populations","volume":"19","author":"Zarkasi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-024-02217-y","article-title":"Oral-gut microbial transmission promotes diabetic coronary heart disease","volume":"23","author":"Li","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1679085","DOI":"10.3389\/fphar.2025.1679085","article-title":"The crosstalk between mitochondrial dysfunction and fatty acid metabolism in heart failure: mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1416403","DOI":"10.3389\/fphar.2024.1416403","article-title":"The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/s23042020","article-title":"Ultra-High sensitivity terahertz microstructured fiber biosensor for diabetes Mellitus and coronary heart disease marker detection","volume":"23","author":"Xue","year":"2023","journal-title":"Sensors (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00011-019-01220-4","article-title":"The influence of ICAM1 rs5498 on diabetes mellitus risk: evidence from a meta-analysis","volume":"68","author":"Mi","year":"2019","journal-title":"Inflamm Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2147\/JIR.S502203","article-title":"Identification of necroptosis and immune infiltration in heart failure through bioinformatics analysis","volume":"18","author":"Zhu","year":"2025","journal-title":"J Inflamm Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-022-01531-7","article-title":"Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China","volume":"21","author":"Yang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"107952","DOI":"10.1016\/j.compbiomed.2024.107952","article-title":"Predicting coronary heart disease in Chinese diabetics using machine learning","volume":"169","author":"Ma","year":"2024","journal-title":"Comput Biol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1210\/clinem\/dgae100","article-title":"Microvascular disease, cardiovascular health, and risk of coronary heart disease in type 2 diabetes: a UK biobank study","volume":"109","author":"Chen","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-022-01494-9","article-title":"Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease","volume":"21","author":"Karagiannidis","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tcm.2021.04.002","article-title":"Coronary heart disease risk: low-density lipoprotein and beyond","volume":"32","author":"Shaya","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"33197261427837","DOI":"10.1177\/00033197261427837","article-title":"Effect of SGLT2 inhibitors on atrial electromechanical delay in patients with type 2 diabetes","volume":"12","author":"Erzurum","year":"2026","journal-title":"Angiology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.47482\/acmr.1346676","article-title":"The effect of SGLT2 inhibitors on cardio-electrophysiological balance index in diabetic patients with preserved ejection heart failure","volume":"4","author":"G\u00f6kalp","year":"2023","journal-title":"Archives of Current Medical Research"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s11886-023-01999-z","article-title":"Screening for coronary artery disease in patients with diabetes","volume":"25","author":"Saraste","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12872-024-03970-4","article-title":"Radiomics of pericoronary adipose tissue on computed tomography angiography predicts coronary heart disease in patients with type 2 diabetes mellitus","volume":"24","author":"Miao","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jare.2023.12.009","article-title":"Lipidomics identified novel cholesterol-independent predictors for risk of incident coronary heart disease: mediation of risk from diabetes and aggravation of risk by ambient air pollution","volume":"65","author":"Li","year":"2024","journal-title":"J Adv Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2337\/dc24-1489","article-title":"Incremental prognostic value of a coronary heart disease polygenic risk score in type 2 diabetes","volume":"47","author":"Mordi","year":"2024","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"110732","DOI":"10.1016\/j.diabres.2023.110732","article-title":"Incidence and risks of coronary heart disease and heart failure in Japanese patients with type 2 diabetes mellitus: the fukuoka diabetes registry","volume":"201","author":"Iwase","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2159660","DOI":"10.1155\/2022\/2159660","article-title":"The efficacy of double-heart nursing in combination with seaweed polysaccharide for patients with coronary heart disease complicated with diabetes: a pilot, randomized clinical trial","volume":"2022","author":"Hu","year":"2022","journal-title":"Dis Markers"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1745362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:35:22Z","timestamp":1780547722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1745362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2026.1745362"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1745362","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1745362"}}